LENSAR (LNSR) is being acquired by Alcon for $14 per share, with an additional CVR offering up to $2.75 based on future ...

Jayne Juvan and Dan McClain of Tucker Ellis LLP discuss the slowdown in M&A transactions, in light of the rollout of tariffs, and ways to bridge the gap through contingent consideration where some of ...

In mergers and acquisitions, CFOs must identify whether payments are contingent consideration or postacquisition compensation ...

Following a review process conducted with the assistance of its legal and financial advisors, the Kronos Bio Board of ...

At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for ...

each pursuant to the contingent value rights agreement (the “CVR Agreement”). Following a review process conducted with the assistance of its legal and financial advisors, the Kronos Bio Board ...

Novartis has signed an agreement to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen.

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

Novartis Acquires Regulus Therapeutics in $1.7 Billion Deal for ADPKD Treatment ...